Comparative Effectiveness of Environmental Intervention and Standard Care in Ability to Reduce Pharmacologic Therapy for Asthma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 243
- 试验地点
- 3
- 主要终点
- Step down of medication
研究概览
简要总结
Exposure to household allergens is a major contributor to asthma symptoms. Aggressive measures to reduce household allergens has the potential to reduce asthma symptoms and the need for medications to control asthma. The investigators plan to enroll patients aged 6 and above into a single blind, randomized study comparing intensive environmental intervention with usual asthma care over a 48 week study period. All subjects will have asthma treatment optimized according to guideline based care. Subjects will be randomized to an aggressive environmental remediation arm versus distribution of written materials regarding allergen reduction ("usual care"). Primary outcome measure will be ability to reduce asthma step therapy. Secondary outcomes include measures of lung function, asthma biomarkers and quality of life.
详细描述
Research question(s):
In individuals with atopic asthma who are being treated with inhaled corticosteroids with or without long acting beta agonists (1 of 6 possible steps of treatment), aggressive environmental intervention to reduce exposure to home allergens is more likely to lead to one step reduction in asthma controller therapy, improved asthma control and improved biomarkers of airway inflammation than is usual care.
Scientific abstract:
Environmental exposure to indoor allergens is a major contributor to asthma impairment and risk, particularly among asthmatic patients residing in inner cities. The investigators plan a randomized controlled trial to assess the effect of individualized, comprehensive, multifaceted indoor allergen avoidance measures on ability to step down asthma controller therapy in adults and children greater than 6 years with mild to severe persistent asthma.
Specifically,
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Care Provider)
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical history consistent with asthma in male and female subjects ages 6 and above.
- •Need for controller therapy demonstrated by current use of a stable dose (at least 4 weeks) of long term asthma controller therapy; or if not receiving long term asthma controller, symptoms consistent with persistent asthma (eg. Symptoms > 3x per week).
- •Prebronchodilator FEV1 > 40% predicted at screening (V0)
- •Positive skin test (defined as wheal greater than 3 mm in diameter greater than saline negative control) to protein extracts of at least one of 9 common indoor allergens including dust mites, cockroach mix, rat, mouse, Alternaria, Cladosporium, Aspergillus, cat and dog tested at Visit 0 (or positive RAST test to at least on aeroallergen if FEV1<60% at Visit 0 precluding allergen skin testing.)
- •Evidence of at least one allergen in household dust which matches skin test positivity or RAST testing (overlap to be checked and recorded at V3).
- •Asthma confirmed by either reversibility to 4 puffs albuterol greater than or equal to 12% in FEV1 at V0 OR PC20 FEV1 methacholine of less than or equal 16 mg/ml at or up to 30 days previous to V
- •Sleeps overnight at same address at least 5 times per week.
排除标准
- •Significant medical illness other than asthma including other chronic respiratory illness (eg emphysema, cystic fibrosis)
- •Currently receiving immunotherapy or received such therapy in the past year
- •Emergency Department (ED) visit for asthma or steroid taper within the past 2 weeks (may be rescreened at a future date).
- •Investigational drug within the past 30 days; anti-IgE therapy within past 6 months
- •Active smoker or greater than 10 pack year history of asthma
- •Asthma requiring mechanical ventilation within the past 5 years
- •Significant occupational exposures as determined by principal investigator.
结局指标
主要结局
Step down of medication
时间窗: V4-V7 (every two months)
Based on subject's lung function and symptoms
次要结局
- lung function(Every visit (every month for two months, then every two months))
- Change in allergen specific serum IgE levels(Visit 3, Visit 5 and Visit 8 (approximately every 4 months))
- Fractional excretion of nitric oxide(V3-V8 (every two months))
- Change in airway hyper-responsiveness(Visit 1 and Visit 7 (initial visit and at month 10))
- Asthma exacerbations(Every visit (every two weeks for two months, then every two months))
- Asthma symptom score(V3-V8 (every two months))
研究者
Emily DiMango, MD
Professor of Clinical Medicine
Columbia University